Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI reads brain scans to spot Parkinson's early

NCT ID NCT05080296

Diagnosis Sponsor: Central Hospital, Nancy, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether artificial intelligence (AI) can help diagnose Parkinson's disease by analyzing brain scans called DaTSCAN SPECT. Researchers used machine learning to tell the difference between healthy people, those with Parkinson's, and those with similar conditions. The study looked at scans from over 1,600 patients taken between 2011 and 2017. If the AI works well, it could make diagnosis faster and more accurate.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
machine learning algorithm
What this could lead to
If successful, this AI tool could help doctors diagnose Parkinson's disease earlier and more accurately, reducing misdiagnosis.
What could go wrong
This is a completed analysis of existing scans, not a real-world test. The AI may not work as well in different hospitals or with diverse patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,664 people

The number who actually took part.

Started

Dec 2021

Finished

Sep 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All Patients who performed a DaTSCAN SPECT scan in the nuclear medicine department of the Nancy CHRU between 21/11/2011 and 01/09/2017.

Ages

18 to 85 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients who performed a DaTSCAN SPECT scan in the nuclear medicine department of the Nancy CHRU between 21/11/2011 and 01/09/2017. * Reviews that took place between 11/21/2011 and 9/1/2017 were repatriated from PACS to the processing consoles.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Datscan spect scans are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Datscan spect scans

Contacts and locations

Locations

  • Nuclear medicine department CHRU de NANCY

    Vandœuvre-lès-Nancy, 54511, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.